Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2025-04-25 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
2024年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled '2024年度董事会工作报告' which translates to '2024 Annual Board of Directors Work Report'. It details the activities, meetings, and decisions of the board of directors throughout the year 2024, including the number of meetings, agenda items, and resolutions passed. It also discusses governance, internal controls, investor relations, and plans for 2025. The content is a comprehensive report on the board's work and governance activities over the year, not just an announcement or summary. It is not a full annual report (10-K) but specifically focuses on the board's work and governance. This fits the category of Board/Management Information (MANG), which covers announcements about board activities and management information. The document length (5793 characters) and detailed content support this classification rather than a brief announcement or a full financial report.
2025-04-25 Chinese
关于2024年限制性股票激励计划部分限制性股票回购注销完成的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the completion of repurchase and cancellation of restricted stocks under the 2024 restricted stock incentive plan. It details the number of shares repurchased, the price, the approval procedures, and the impact on the company's share capital structure. The document is a formal announcement about a share repurchase and cancellation event related to the company's stock incentive plan. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. The content fits the category of a Transaction in Own Shares (POS), which covers company buybacks or sales of its own shares, including repurchase and cancellation of restricted stock.
2025-04-11 Chinese
关于诉讼进展暨收到二审《民事判决书》的公告
Legal Proceedings Report Classification · 100% confidence The document is an announcement regarding the progress of a legal case involving the company, including details about a second-instance civil judgment and its implications. It references court decisions, litigation stages, and potential financial impacts but does not contain financial statements or detailed financial data. The content is focused on legal proceedings and updates rather than financial reporting or other categories. Therefore, the document fits the category of Legal Proceedings Report (LTR). The document length is short and it is not a report publication announcement or certification, so it is not RPA or RNS.
2025-03-31 Chinese
关于回购股份注销完成暨股份变动的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the completion of a share repurchase and the subsequent cancellation of those shares by Harbin Yuheng Pharmaceutical Co., Ltd. It details the number of shares repurchased and cancelled, the dates of these actions, the impact on the company's share capital structure, and compliance with relevant regulations. There are no financial statements or detailed financial performance data included, and the document is focused on the share repurchase and cancellation event. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company buying back or selling its own shares.
2025-03-31 Chinese
关于使用闲置自有资金进行委托理财的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the progress of using idle self-owned funds for entrusted wealth management. It includes specifics about various financial products purchased, amounts, risk ratings, investment periods, and risk control measures. The document is a formal disclosure about the company's financing activities related to the use of idle funds in wealth management products. It does not contain financial statements or quarterly/yearly financial results, nor is it a report like an annual or interim report. It is not a certification or a short announcement of a report publication. The content fits best with an update on company financing activities, specifically about capital usage and investment in financial products. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (6440 characters) and detailed content support this classification with high confidence.
2025-03-27 Chinese
关于完成法定代表人变更并换领营业执照的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the change of the company's legal representative and the completion of the business license reissuance. It references board and shareholder meeting resolutions but does not contain financial data or detailed management discussion. The document length is short (689 characters) and it is an official announcement about management changes, specifically the legal representative change. This fits the category of Board/Management Information (MANG).
2025-03-24 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.